Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

4.020 -0.050 (-1.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Affimed Ord Shs

< Previous 1 2 3 4 5 6 Next >
Where Affimed Stands With Analysts
Via Benzinga
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Affimed Earnings Preview
Via Benzinga
3 Cheap Stocks to Buy Under $1 in August 2023
Penny stocks are risky, but here are three stocks under $1 to buy that are potentially rewarding for bold investors willing to roll the dice. 
Via InvestorPlace
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
From Affimed N.V.
Via GlobeNewswire
Analyst Ratings for Affimed
Via Benzinga
Affimed: Q1 Earnings Insights
Via Benzinga
Affimed's Earnings Outlook
Via Benzinga
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
From Affimed N.V.
Via GlobeNewswire
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the 2023 Jefferies Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For May 23, 2023
Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million. 
Via Benzinga
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
From Affimed N.V.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! 
Via InvestorPlace
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
From Affimed N.V.
Via GlobeNewswire
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
From Affimed N.V.
Via GlobeNewswire
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.